Archives
Network Pharmacology Reveals SFI's Anti-Glioma Actions via S
2026-06-16
Network Pharmacology Reveals SFI's Anti-Glioma Actions via SRC/PI3K/AKT
Study Background and Research Question
Gliomas account for up to half of all primary brain tumors and are characterized by aggressive proliferation, invasive growth, and poor patient prognosis, with median survival rarely exceeding 17 months. Standard therapies—surgery, radiotherapy, and chemotherapy—offer only incremental improvements, necessitating the search for novel therapeutic strategies. Shenqi Fuzheng injection (SFI), a clinical formulation derived from Codonopsis pilosula and Astragalus membranaceus, is widely used in China as an adjunct to cancer chemotherapy, yet its molecular mechanisms of action in glioma remain insufficiently understood. The reference study (Li et al., 2024) set out to clarify how SFI affects glioma cell proliferation and migration, employing a network pharmacology framework to identify key molecular pathways and validate findings through both cellular and animal models.Key Innovation from the Reference Study
The principal innovation of this work lies in its integration of network pharmacology with experimental validation to dissect the anti-glioma mechanisms of SFI. Unlike traditional reductionist approaches, network pharmacology enables the mapping of complex herbal formulations to their molecular targets and associated signaling pathways in a data-driven manner. By merging computational target prediction with wet-lab assays, the study systematically traced SFI's effects to the SRC/PI3K/AKT signaling cascade—a pathway central to cell proliferation, survival, and migration—thereby providing a mechanistic rationale for SFI's clinical efficacy in glioma adjuvant therapy.Methods and Experimental Design Insights
The research was conducted in several stages:- Network pharmacology: Putative targets of SFI and glioma were compiled from publicly available databases, resulting in 3,343 glioma-associated genes and 110 SFI-related targets, with 79 overlapping candidates identified for further analysis.
- In vitro validation: Human glioma cell lines U87 and T98G were exposed to SFI, and proliferation was assessed using CCK-8, EdU incorporation, and plate cloning assays. Migration and invasion were quantified via scratch and Transwell assays, while cell cycle distribution and EMT marker expression were evaluated by flow cytometry, immunofluorescence, and Western blotting.
- In vivo validation: Mouse models bearing subcutaneous GL261 glioma tumors were treated with SFI, and outcomes were measured using HE staining and immunohistochemistry to assess tumor growth and molecular pathway activity.
- Bioinformatics enrichment: Functional annotation and pathway enrichment analyses highlighted the SRC/PI3K/AKT axis as a central node in the intersection between SFI targets and glioma biology.
Core Findings and Why They Matter
The study's findings are multifaceted:- Proliferation inhibition: SFI significantly suppressed proliferation of U87 and T98G cells, inducing S-phase arrest and reducing colony formation (Li et al., 2024).
- Migration and EMT suppression: Exposure to SFI decreased glioma cell migration and invasion, paralleled by downregulation of epithelial-mesenchymal transition (EMT) markers.
- Pathway specificity: Both in vitro and in vivo, SFI treatment led to decreased phosphorylation of SRC, PI3K, and AKT, supporting the conclusion that the SRC/PI3K/AKT axis mediates its anti-glioma effects.
- Tumor growth reduction in vivo: In mouse models, SFI administration markedly reduced tumor volume and weight, further validating its anti-angiogenic and anti-proliferative activities in a physiologically relevant context.
Comparison with Existing Internal Articles
Recent internal analysis, such as the article "AAL-993: Advancing Tumor Angiogenesis Research with Precision", highlights the importance of high-specificity VEGF receptor inhibitors like AAL-993 for dissecting tumor angiogenesis and metastasis in preclinical settings. While the SFI study focuses on a traditional herbal formulation and the SRC/PI3K/AKT pathway in glioma, both works converge on the principle that modulation of key signaling axes—whether via phytochemicals or selective small molecules—can yield significant anti-tumor and anti-angiogenic effects. The mechanistic clarity gained from network pharmacology now enables more rational experimental design, including head-to-head comparisons between complex herbal mixtures and targeted inhibitors in defined models of tumor progression.Limitations and Transferability
Despite its integrative approach, the reference study is subject to several limitations. The SFI formulation contains dozens of bioactive compounds, making it challenging to attribute effects to specific molecules or to anticipate off-target activity. While network pharmacology provides a hypothesis-generating framework, its reliance on existing databases and prediction algorithms may miss novel interactions. Additionally, the translational value of findings from murine models to human glioma therapy remains uncertain, and the precise role of angiogenesis inhibition—relative to direct anti-proliferative effects—requires further delineation. These challenges underline the need for more targeted, mechanism-driven studies using well-defined reagents and pathway-specific inhibitors.Protocol Parameters
- SFI in vitro treatment: Typical concentrations ranged from 0.1 to 2 mg/mL for 24–48 h in U87 and T98G cell lines, with dose-response effects observed on proliferation and migration.
- SFI in vivo dosing: In C57BL/6 mouse models bearing GL261 tumors, SFI was administered intraperitoneally at 20 mL/kg daily, with tumor growth monitored over two weeks.
- Pathway analysis: Western blot and immunohistochemistry for phosphorylated SRC, PI3K, and AKT should be performed 24–48 h post-treatment to capture acute pathway modulation.
- Workflow suggestion: When dissecting angiogenesis-specific effects, consider parallel arms with established angiogenesis inhibitors (such as VEGF receptor inhibitors) to delineate direct anti-tumor from anti-vascular mechanisms.